Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer
This study aims to determine the safety and tolerability of combining sequential therapy of Irreversible Electroporation (IRE) and Immunotherapy (IO) for patients with locally advanced unresectable pancreas cancer following first-line treatment with chemotherapy and ablative stereotactic magnetic resonance image-guided adaptive radiation therapy (A-SMART).
Pancreatic Cancer|Locally Advanced Pancreatic Cancer
DRUG: Pembrolizumab|DEVICE: Irreversible Electroporation
Safety and Tolerability, The number of participants who experience a high-grade (grade 3-5) adverse events based on NCI common terminology criteria for adverse events (CTCAE) version 5 related to treatment., Up to 90 days
Progression-Free Survival (PFS), PFS is defined as the time from date of diagnosis to the time of first documented tumor progression or death due to any cause, whichever occurs first., Up to 24 months|Overall Survival (OS), OS is defined as the time from date of diagnosis to the time of death due to any cause., Up to 24 months|Objective Response Rate (ORR), ORR is defined as the proportion of patients with either a partial or complete response according to iRECIST version 1.1 guidelines, measured from date of diagnosis., Up to 24 months
This study aims to determine the safety and tolerability of combining sequential therapy of Irreversible Electroporation (IRE) and Immunotherapy (IO) for patients with locally advanced unresectable pancreas cancer following first-line treatment with chemotherapy and ablative stereotactic magnetic resonance image-guided adaptive radiation therapy (A-SMART).